Login

Log In to SINEORA
Login with your social media account
or
Use your corporate e-mail address
New to SINEORA?
Find the best technology startups for your innovation or join our startup program. Create an account

register

Sign Up: Create your company account

By sign up you get the following benefits:

  • Select best local partner to continuously enrich our pipeline
  • Pre-screening relevant ones
  • Pre-screening the startups in our focused domain, namely AI, Industrial IoT, B2B software, Robotics and Blockchain
  • Startups Assessment Report (360-degree view with our originally developed methodology)
  • Deep understanding of corporates’ digital transformation challenges and constraints
  • Focusing on synergized scenario
  • Fine tune process empowered by our algorithm (per initiative)

Select the better description for your innovation company

If you already have an account,

corporate form

startup form

Enterome

Enterome

Privately owned personalized medicine company

59 employees
Launch date : 2011

VALUE PROPOSITION

Enterome is a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health. Enterome’s success is based on its unique ability to identify small proteins and peptides (“effectors”) from gut bacteria that can deliver a therapeutic benefit in humans. Enterome is leveraging this unique ability to develop two highly promising pipelines of clinical and pre-clinical candidates with a focus on cancer, inflammatory and metabolic diseases: - OncoMimics: highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463). EO2401 is in Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463, is about to enter clinical development for indolent non-Hodgkin B-cell lymphomas. - EndoMimics: a new generation of biologics targeting inflammatory diseases (EM101) and metabolic diseases such as Type 2 diabetes. These pipelines have been created using Enterome’s highly efficient proprietary drug discovery platform that uses machine learning and lab assays to interrogate and decode the world’s largest database of gut bacterial proteins, a unique source of novel precision drugs. In addition, Enterome’s clinical candidate Sibofimloc (also referred to as TAK-018) is advancing through Phase 2 clinical trials in Crohn’s disease. Sibofimloc has been partnered with Takeda globally, with Enterome retaining a significant profit share in the US. Enterome is headquartered in Paris (France) and is backed by leading venture capital investors.

Date Investor Amount
Investor Amount

RECENT NEWS

INTERACT WITH THIS STARTUP